Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. on October 6, 2023. The report discloses a material corporate event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of Iris Roth, Ph.D., the Company's Chief Operating Officer. Dr. Roth will cease serving in this role effective at 11:59 p.m. Eastern Time on October 10, 2023.
Outlook, Risks, and Unusual Items
As part of the departure, the Company expects to enter into a release agreement with Dr. Roth. Under this agreement, the Company will provide severance benefits in accordance with her Employment Agreement dated February 8, 2023. No other risks, contingencies, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the effective date of the COO departure (October 10, 2023).
- Review the previously filed Employment Agreement (Exhibit 10.1 to the February 13, 2023 Form 8-K) to understand the specific severance terms.
- Monitor subsequent filings for the appointment of a new Chief Operating Officer or interim leadership.